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Abstract
We have seen a notable increase in the application of PD-1/PD-L1 inhibitors for the treatment of several solid and
hematogenous malignancies including metastatic melanoma, non-small-cell lung cancer and lymphoma to name a
few. The need for biomarkers for identification of a suitable patient population for this type of therapy is now
pressing. While specific biomarker assays have been developed for these checkpoint inhibitors based on their
respective epitopes, the available studies suggested the clinical utility of these biomarker assays is for response
stratification and not patient selection. Further improvement in assay development is needed to utilize this type of
assay in identification of ideal patient population for this therapy.
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Introduction
Immune modulation therapies have seen an impressive
growth over the last decade [1]. Recently, inhibitors of
programmed cell-death receptor (PD-1) and its associated
ligand (PD-L1) have gained significant attention from the
oncology community. PD-L1, typically expressed on the
surface of healthy cells, binds PD-1 on primed cytotoxic T
cells thereby inhibiting cell-mediated attack [1–3]. Mul-
tiple studies reported worse outcomes in tumors express-
ing PD-L1 [2, 3]. Purportedly, the expression of this ligand
on tumor cells confers protection against immune-
mediated attacks on tumor cells and may account for their
particularly malignant potential. Anti-PD-L1 (or anti-PD-
1) monoclonal antibodies inhibit PD-L1 binding to PD-1
and allow T cell activity at this immune checkpoint.
Several clinical trials using these antibodies for the treat-
ment of malignancies such as melanoma, non-small-cell
lung cancer (NSCLC), head and neck cancer, renal cell
cancer, urothelial cancer and lymphoma have shown great
promise in prolonging survival [4–10].
However, not all patients respond to PD-1/PD-L1
inhibitors. Thus, predicting the likelihood of response to
treatment would aid in appropriate patient selection for
these drugs. Immunohistochemistry (IHC) biomarker as-
says for respective PD-1/PD-L1 inhibitors were designed
to screen for the presence of specific PD-1/PD-L1 epi-
topes as well as to estimate the percentage of T cells or
tumor cells expressing this receptor or ligand. At this
time, 4 FDA-approved IHC biomarker assays have been
designed [10]. Their ability to consistently and reprodu-
cibly quantify proportion of cells expressing PD-L1 has
been evaluated in prospective trials. Given the inherent
heterogeneity of gene expression between individual
tumors and among tumor cells within the same tumor
nodules, there are concerns that any single assay using a
fixed percentage of PD-L1 positive tumor cells could
accurately determine the appropriate patients for treat-
ment [11, 12]. This is reflected in the finding that PD-1/
PD-L1 inhibitors appear to have activity in a subset of
individuals who do not meet the IHC bioassay cutoff.
Furthermore, recent studies suggested that several
additional factors could be involved in the response to
anti-PD-1/PD-L1 antibodies.
Current PD-1 & PD-L1 inhibitors
Among the first generation of these drugs, Pembrolizu-
mab (an anti PD-1 antibody) was approved for treatment
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of NSCLC [13–16] and melanoma [17–20] in 2014.
Pembrolizumab has also recently been approved for use
in advanced head and neck squamous cell carcinoma
(HNSCC) [21, 22]. Nivolumab (an anti PD-1 antibody)
was approved for melanoma in 2014 [23–28] NSCLC in
2015 [29–32] and renal cell carcinoma in 2015 [33, 34].
Pembrolizumab and Nivolumab have been demonstrated
to improve overall and progression free survival in the
above-mentioned tumors. Atezolizumab (an anti PD-L1
antibody) has received FDA designated breakthrough
drug status for two malignancies. Clinical trials are cur-
rently underway for both metastatic NSCLC [35–37]
and for urothelial carcinoma [38]. Durvalumab (an anti-
PD-L1 antibody) is also being evaluated in clinical trials
for the treatment of NSCLC (phase III) [39] and bladder
cancer (phase III) [40, 41]. Pidilizumab (an anti PD-1
antibody) is currently being tested in the treatment of
large B cell lymphoma (Phase II completed) [42]. Finally,
Avelumab (an anti PD-L1 antibody) is currently being
tested in patients with Merkel cell carcinoma (Phase II)
[43] and NSCLC (Phase III) [44].
Current PD-1/PD-L1 bioassays
Several studies examining the usefulness of PD-L1 IHC
assays have demonstrated a direct correlation of response
rate to PD-L1 expression level. The distinction between a
companion assay and a complementary assay should be
underlined here. A companion assay is one that is consid-
ered to be essential to the use of its corresponding drug.
Pembrolizumab is FDA approved only when used in con-
junction with the Dako 22C3. Conversely, the other bioas-
says are considered complementary in that their use is
recommended in order to optimize appropriate patient
selection but is not considered mandatory for the use of
its associated drug [45]. The cutoff values for these assays
vary from as low as 1% to as high as 50%. To allow for
comparison, sensitivity (SENS) and specificity (SPEC) of
the bioassay for a given malignancy were calculated based
on the reported objective response rate in individuals who
were considered to have PD-L1 positive tumors (ORR+)
and that of the individuals who were considered to have
PD-L1 negative tumors (ORR-). Sensitivity was calculated
as a ratio of true positives (ORR+) to the sum of true posi-
tives (ORR+) and False Negatives (ORR-). Specificity was
calculated as a ratio of true negatives (1-ORR-) to the sum
of true negatives (1-ORR-) and false positives (1-ORR+).
Pembrolizumab is currently approved for the treat-
ment of NSCLC, advanced HNSCC and advanced
melanoma. Its companion IHC biomarker assay, Dako
22C3, is used to detect PD-L1 in all three types of malig-
nancies. It is the only assay that has FDA companion
status [45]. This exceptional status is due to the assays
reliability when testing for PD-L1 positivity making it an
essential tool when assessing which candidates are
appropriate for treatment with Pembrolizumab. The
Dako 22C3 PD-L1 positivity cutoff is 1% for melanoma.
The average ORR+ is 39% for PD-L1 positive tumors
and the average ORR- is 10% for PD-L1 negative tumors.
These estimates are based on the findings from Daud et
al. [19] who graded PD-L1 positivity and negativity
based on the MEL score. Using a 1% expression as a cut-
off, MEL scores of 0 and 1 were considered negative
whereas MEL scores of 2,3,4 and 5 were considered
positive. The ORR- and ORR+ were weighted averages
of MEL 0 and 1 and MEL 2–5 respectively. The associ-
ated SENS and SPEC for this bioassay are 80 and 60%,
respectively. The cutoff for HNSCC PD-L1 positivity is
also 1%. The ORR+ and ORR- are 22% and 4%, respect-
ively [21, 22]. SENS is 85% and SPEC is 55%. For
NSCLC, the Dako 22C3 PD-L1 positivity cutoff is 50%.
ORR+ and ORR- are 41 and 13%, respectively [13–15].
The SENS is 76% and the SPEC is 60% (Table 1).
Nivolumab is currently approved for the treatment of
squamous and non-squamous NSCLC, advanced RCC
and advanced melanoma. Its companion PD-L1 IHC
biomarker assay, Dako 28–8, is only used in tumor tis-
sue from NSCLC and melanoma [46]. In the case of
RCC, the PD-L1 expression detected on Dako 28–8 was
not predictive of response to Nivolumab [33, 34]. Nivo-
lumab is considered second line therapy for RCC regard-
less of PD-L1 status. For melanoma, the Dako 28–8 PD-
L1 positivity cutoff is 5%. The ORR+ was 57% and the
ORR- was 41% and the associated SENS and SPEC are
58 and 49%. An interesting set of findings was brought
about when Nivolumab was combined with Ipilimumab,
an anti- CTLA4 antibody. The ORR+ and ORR- are 72
and 55%, respectively and the associated SENS and
SPEC for this bioassay are 57 and 54%, respectively [25,
27, 28]. The Dako 28–8 cutoff for NSCLC is 1%. For
non-squamous NSCLC, the ORR+ and ORR- are 19 and
9%, respectively [32]. SENS is 68% and SPEC is 53%. For
squamous NSCLC, there was no significant difference
between ORR+ and ORR- which could be estimated at
approximately 20% [30, 31]. The SENS and SPEC could
therefore not be calculated (Table 1).
Durvalumab is currently approved for the treatment of
NSCLC and bladder cancer. Its companion IHC bio-
marker assay is Roche Ventana SP263 [47]. The SP263
PD-L1 positivity cutoff is 25% for NSCLC. The ORR is
27% for PD-L1 positive tumors and 5% for PD-L1
negative tumors [39]. The associated SENS and SPEC
are 84 and 78%, respectively. A recent study compared
Durvalumab alone to combination therapy with Durva-
lumab and Tremelimumab (an anti CTLA-4 antibody).
The ORR+ and ORR- were 22.5 and 29% respectively in-
dicated that the ORR appeared to be negatively affected
by higher PD-L1 expression. The SENS and SPEC were
36 and 48%. The SP263 cutoff for bladder cancer is also
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25%. The ORR+ and ORR- are 46 and 0%, respectively
[40, 41] with an associated SENS of 100% and SPEC of
65% (Table 1).
Atezolizumab is currently approved for treatment of
metastatic NSCLC and urothelial cancer [35]. Its com-
panion IHC biomarker assay is Roche Ventana SP142.
The SP142 PD-L1 positivity cutoff is 50% for NSCLC.
ORR+ is 45% and ORR- is 14% [36, 37]. The associated
SENS and SPEC are 76 and 61%, respectively. The cutoff
for urothelial cancer is 1%. The ORR+ and ORR- are
27% and 15%, respectively [38]. However, in this study,
the ORR- included both patients with IHC staining <1%
and patients with IHC staining between 1 and 5%.
Therefore, the SENS and SPEC for SP142 in urothelial
cancer could not be calculated (Table 1).
In general, the average specificity for these assays is
58%. Thus, approximately 42% of patients who are not
likely to respond to treatment are considered PD-L1+.
Furthermore, the average overall sensitivity of these
assays with their respective cutoff levels is 72%; suggest-
ing an average of 28% of patients who are considered
PD-L1 negative may benefit from this type of treatment.
The estimates are based on the figures seen in table.
Factors influencing PD-L1 expression
The mechanism of PD-L1 expression is complex. Several
factors appear to influence both PD-L1 expression and
response to treatment [48–52]. BRAF and MEK muta-
tions contribute to dysfunction of the Ras-Raf-MEK-
ERK Map kinase mutations that are present in greater
than 90% of melanomas. Specific BRAF mutations when
pretreated with Dabrafenib have been associated with
reduced response to PD-1/PD-L1 inhibition in melan-
oma [53–55]. However, when Dabrafenib was combined
with MEK suppressor Tremelimumab, an improved
response to PD-L1 inhibition was noted [55, 56].
Similarly, blockade of mutated BRAF and MEK was
associated with improved response to PD-1/PD-L1 in-
hibition in NSCLC. Another interesting relationship is
the one between mutations in EGFR and EML4-ALK
and the expression of PD-L1. Recent studies indicate
that EGFR mutations and rearrangements in EML4-ALK
are associated with up regulation of PD-L1 synthesis and
expression in NSCLC [57–59]. This was further estab-
lished when patients with these mutations were treated
with tyrosine kinase inhibitors and exhibited in lower
overall response to PD-L1 blockade [60]. The presence
of KRAS in the tumor also appears to be associated with
increased expression of PD-L1 [60]. In a case report,
KRAS pretreatment is reported to have increased re-
sponse to Nivolumab in a patient who had not
responded to several other treatment courses [61]. In
addition, PD-L1 expression can increase due to local
pro-inflammatory factors. Cigarette smoking in patients
with NSCLC appears to increase the number of lympho-
cytes present as well as the overall proportion of PD-L1
present [62]. Platinum based chemotherapy [63] also ap-
pears to affect the tumor environment in a similar way
to cigarette smoke. Additional studies have attributed
tumor resistance to immunotherapies to immunosup-
pressive events occurring in the tumor microenviron-
ment. Several of the mechanisms have been studied in
clinical samples and validated in mouse models. The
most important may be extrinsic suppression of CD8+
effector cells by CD4 + CD25 + FoxP3+ regulatory T cells
(Tregs) [64, 65]. The metabolic deregulation via trypto-
phan catabolism by indoleamine-2,3-dioxygenase (IDO)
may also play a role [66]. With multiple intrinsic and
Table 1 Biomarker assays for anti-PD-1/PD-L1 drugs and associated outcomes
Bioassay Drug Disease Target Cut Offb ORR+c ORR-d SENSe SPECf
Roche Ventana SP263 Durvalumab NSCLCa 25% 27% 5% 84% 78%
Roche Ventana SP263 Durvalumab + Tremelimumab NSCLC 25% 22.5% 29% 36% 48%
Roche Ventana SP263 Durvalumab Bladder Cancer 25% 46% 0% 100% 65%
Roche Ventana SP142 Atezolizumab Metastatic NSCLC 50% 45% 14% 76% 61%
Roche Ventana SP142 Atezolizumab Urothelial Carcinoma 1% 27% 13% NA NA
Dako 22C3 Pembrolizumab NSCLC 50% 41% 13% 76% 60%
Dako 22C3 Pembrolizumab HNSCC 1% 22% 4% 85% 55%
Dako 22C3g Pembrolizumab Melanoma 1% 39% 10% 80% 60%
Dako 28-8 Nivolumab Non-Squamous NSCLC 1% 19% 9% 68% 53%
Dako 28-8 Nivolumab Squamous NSCLC 5% 20% 20% NA NA
Dako 28-8 Nivolumab Melanoma 5% 57% 41% 58% 49%
Dako 28-8 Nivolumab + Ibilimumab Melanoma 5% 72% 55% 57% 54%
aNSCLC: Non-Small-Cell Lung Cancer – bCut Off: Proportion of tumor cells expressing PD-L1 below which tumor is considered PD-L1 negative. – cORR+
Objective Response Rate in PD-L1 positive tumors. – dORR-: Objective Response Rate in PD-L1 negative tumors. – eSensitivity of bioassay for predicting response
to PD-L1 blockade based on established cut off. fSpecificity of bioassay for predicting response to PD-L1 blockade based on established cut off. – gORR+ and
ORR- based on weighted average of corresponding MEL scores
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extrinsic factors influencing PD-L1 expression, PD-L1
expression may vary over time. Since tumor cells can
exert an adaptive immune response over time, tumor tis-
sue may express little PD-L1 at the moment of tissue
sampling for IHC staining but expression may increase
considerably at later time point in the disease course
[52, 67, 68].
Conclusion
Modification of specific checkpoints in anti-tumor im-
mune response has resulted in significant improvement
for the treatment of various malignancies. The relation-
ship between tumor expression of PD-L1 and patient
outcome has been established. However, the currently
available IHC biomarker assays could not provide clinic-
ally meaningful identification of responders and non-
responders [11, 12, 67, 68]. The sensitivity and specificity
of the IHC assays are generally poor. The stringent ap-
plication of the results of these assays would exclude up
to 28% of individuals who may benefit from treatment
and include up to 42% of patients who may not benefit.
Several tumor and patient characteristics appear to in-
fluence response to PD-1/PD-L1 inhibitor and should be
considered when selecting patients for this treatment. Pro-
viding several tissue samples and obtaining tissue samples
at different time intervals may allow for more accurate de-
termination of appropriate patient for treatment.
A direct comparison of the clinical utility of these
diagnostic assays for lung cancer was recently com-
pleted. In the Blueprint PD-L1 IHC Assay Comparison
Project, the Pathology Committee of the International
Association for the Study of Lung Cancer joined efforts
with 6 of the commercial stakeholders (Astra Zeneca,
Bristol Myers Squibb, Dako, Merck Sharpe Dohme,
Roche/Genentech Pharmaceuticals, and Roche Ventana
Diagnostics) to compare these tests. 3 of the 4 assays
showed similar results but the SP142 demonstrated sig-
nificantly less expression [72]. The interchangeability of
the current assays is likely to be a challenge [69–71].
One promising strategy is the study of mRNA via in situ
hybridization aimed at providing useful data for predict-
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